ENTX — Entera Bio Cashflow Statement
0.000.00%
- $84.54m
- $71.97m
- $0.18m
Annual cashflow statement for Entera Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -11.2 | -12.2 | -13.1 | -8.89 | -9.54 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 0.947 | 1.88 | 2.17 | 1.69 | 2.55 |
Other Non-Cash Items | |||||
Changes in Working Capital | -0.351 | 1.41 | -1.83 | -0.195 | 0.112 |
Change in Accounts Receivable | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -10.6 | -9.06 | -12.5 | -7.31 | -6.82 |
Capital Expenditures | -0.053 | -0.017 | -0.047 | -0.017 | -0.003 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | -0.055 | 0 | — |
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.053 | -0.017 | -0.102 | -0.017 | -0.003 |
Financing Cash Flow Items | — | — | — | -0.58 | -0.323 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 4.05 | 25.4 | 0.013 | 6.04 | 4.48 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -6.56 | 16.3 | -12.6 | -1.29 | -2.35 |